Watch Out For Early Effects Of SPC Waiver, UK Firms Told
Executive Summary
Uncertainties in the new EU supplementary protection certificate manufacturing waiver legislation means both holders of SPCs and those who plan to use the waiver need to closely monitor how the system works from the outset.
You may also be interested in...
UK’s No-Deal Brexit Plans For SPC Waiver Could Reduce IP Rights, Warns BIA
The UK’s plans to amend the supplementary protection certificate waiver legislation in the event of a no-deal Brexit could lead to the curtailment of IP protections, not only the terms of SPCs but regulatory data protection and orphan exclusivity too, the BIA claims.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.